Table II.
Distribution of cases with SMG involvement according to clinical T stage.
| Tumour site | Patients (n) | Direct SMG invasion (n) | Invasion through metastatic LN (n) | Metastasis to SMG (n) | Total SMG involvement(n) |
|---|---|---|---|---|---|
| Tongue | 108 | 3 (T3,T3,T4) |
2 (T2,T2) |
1 (T2) |
6 (4.2%) |
| FOM | 33 | 4 (T3,T4,T4,T4) |
1 (T4) |
0 | 5 (11.3%) |
| Buccal mucosa | 24 | - | 1 (T4) |
- | 1 (3.7%) |
| Palate | 22 | - | - | - | 0 |
| RMT | 21 | - | - | - | 0 |
| AR | 16 | - | - | - | 0 |
| Lip | 12 | 1 (T4) |
0 | 0 | 1 (7.6%) |
| Total | 236 | 8 | 4 | 1 | 13 (4.4%) |
(LN: Lymph-node, n: number, FOM: floor of mouth, AR: Alveolar ridge, RMT: Retromolar trigon, SMG: Submandibular gland)